| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
12,608 |
11,210 |
$3.69M |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
12,176 |
10,719 |
$2.94M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
53,704 |
41,493 |
$2.58M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
20,153 |
14,711 |
$1.47M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
6,976 |
5,279 |
$520K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
5,879 |
4,631 |
$431K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
27,377 |
22,198 |
$423K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
8,940 |
7,874 |
$413K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
5,161 |
4,073 |
$345K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
12,555 |
10,225 |
$229K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,847 |
2,295 |
$227K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,994 |
2,365 |
$217K |
| 99381 |
|
1,100 |
1,000 |
$92K |
| 94760 |
|
36,162 |
28,980 |
$86K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,202 |
2,777 |
$79K |
| 92587 |
|
6,423 |
5,321 |
$78K |
| 90670 |
|
4,028 |
3,103 |
$70K |
| 96127 |
|
6,967 |
5,984 |
$69K |
| D1206 |
Topical application of fluoride varnish |
2,643 |
2,064 |
$65K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,515 |
2,152 |
$63K |
| 99383 |
|
709 |
571 |
$62K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
1,157 |
809 |
$61K |
| 99000 |
|
2,438 |
2,016 |
$46K |
| 90648 |
|
3,414 |
2,804 |
$34K |
| 99215 |
Prolong outpt/office vis |
661 |
466 |
$33K |
| 83655 |
|
2,733 |
2,076 |
$32K |
| 90633 |
|
3,420 |
2,721 |
$31K |
| 96160 |
|
2,354 |
1,908 |
$30K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
2,526 |
2,246 |
$29K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
216 |
210 |
$29K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,035 |
1,334 |
$29K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
883 |
715 |
$28K |
| 81002 |
|
10,241 |
8,510 |
$26K |
| 90710 |
|
2,238 |
1,734 |
$25K |
| 99382 |
|
292 |
229 |
$25K |
| 90723 |
|
2,330 |
1,927 |
$24K |
| 90651 |
|
1,765 |
1,480 |
$23K |
| 90680 |
|
2,202 |
1,715 |
$23K |
| 90686 |
|
2,392 |
1,983 |
$23K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,245 |
1,290 |
$22K |
| 99384 |
|
206 |
179 |
$20K |
| 92551 |
|
1,280 |
1,144 |
$19K |
| 90734 |
|
1,743 |
1,458 |
$18K |
| 90700 |
|
1,888 |
1,492 |
$18K |
| 36416 |
|
4,186 |
3,332 |
$16K |
| 90716 |
|
1,264 |
994 |
$15K |
| 90696 |
|
1,518 |
1,161 |
$14K |
| 71046 |
Radiologic examination, chest; 2 views |
830 |
574 |
$14K |
| 90698 |
|
1,283 |
947 |
$13K |
| 93000 |
|
638 |
571 |
$13K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
130 |
121 |
$13K |
| 90715 |
|
1,257 |
1,030 |
$13K |
| 99460 |
|
196 |
188 |
$12K |
| 90707 |
|
1,064 |
811 |
$11K |
| 85018 |
|
4,971 |
3,897 |
$11K |
| 90744 |
|
1,187 |
899 |
$10K |
| 0071A |
|
247 |
232 |
$10K |
| 99173 |
|
1,219 |
1,044 |
$9K |
| 0072A |
|
238 |
215 |
$9K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
184 |
170 |
$9K |
| 69210 |
|
374 |
290 |
$8K |
| 90713 |
|
616 |
510 |
$6K |
| 99174 |
|
836 |
555 |
$6K |
| 0001A |
|
143 |
134 |
$6K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
116 |
104 |
$6K |
| 0002A |
|
134 |
130 |
$5K |
| 87631 |
|
48 |
44 |
$5K |
| 86769 |
|
116 |
84 |
$5K |
| 94664 |
|
354 |
259 |
$5K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
96 |
74 |
$4K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
202 |
132 |
$4K |
| 90681 |
|
262 |
234 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,496 |
802 |
$3K |
| 90620 |
|
200 |
171 |
$2K |
| 92558 |
|
187 |
174 |
$2K |
| 90685 |
|
327 |
255 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
24 |
14 |
$2K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
8,086 |
6,376 |
$1K |
| 87807 |
|
128 |
88 |
$1K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
37 |
23 |
$1K |
| 74018 |
|
64 |
46 |
$1K |
| 90621 |
|
78 |
67 |
$1K |
| 69209 |
|
139 |
107 |
$923.00 |
| 99072 |
|
5,718 |
4,905 |
$812.50 |
| 36415 |
Collection of venous blood by venipuncture |
199 |
165 |
$754.29 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
73 |
68 |
$536.28 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
28 |
16 |
$515.97 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
28 |
16 |
$496.86 |
| 96367 |
|
23 |
13 |
$429.98 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
16 |
14 |
$400.00 |
| 86580 |
|
99 |
80 |
$384.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
452 |
301 |
$281.22 |
| 90461 |
|
5,343 |
4,140 |
$172.00 |
| 92550 |
|
14 |
14 |
$163.10 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
915 |
630 |
$92.13 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
43 |
30 |
$29.70 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
124 |
91 |
$27.40 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
134 |
83 |
$18.13 |
| 96161 |
|
421 |
350 |
$2.91 |
| 99051 |
|
1,611 |
1,462 |
$2.77 |
| 99188 |
|
19 |
15 |
$0.00 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
19 |
12 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
155 |
127 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
57 |
44 |
$0.00 |